Daiwa Securities Group Inc. Increases Stock Holdings in Eli Lilly And Co (NYSE:LLY)

Daiwa Securities Group Inc. lifted its stake in Eli Lilly And Co (NYSE:LLY) by 3.0% in the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 36,263 shares of the company’s stock after purchasing an additional 1,043 shares during the quarter. Daiwa Securities Group Inc.’s holdings in Eli Lilly And Co were worth $4,055,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. Selective Wealth Management Inc. purchased a new position in shares of Eli Lilly And Co in the 3rd quarter worth approximately $25,000. Enterprise Trust & Investment Co purchased a new position in Eli Lilly And Co during the 3rd quarter valued at $27,000. Garrett Wealth Advisory Group LLC purchased a new position in Eli Lilly And Co during the 3rd quarter valued at $29,000. Candriam Luxembourg S.C.A. boosted its holdings in Eli Lilly And Co by 47.7% during the 3rd quarter. Candriam Luxembourg S.C.A. now owns 270,304 shares of the company’s stock valued at $30,000 after acquiring an additional 87,250 shares during the period. Finally, Prestige Wealth Management Group LLC purchased a new position in Eli Lilly And Co during the 2nd quarter valued at $34,000. Hedge funds and other institutional investors own 77.22% of the company’s stock.

In other news, CFO Joshua L. Smiley bought 929 shares of the stock in a transaction on Friday, October 25th. The stock was acquired at an average cost of $107.59 per share, for a total transaction of $99,951.11. Following the acquisition, the chief financial officer now owns 31,524 shares of the company’s stock, valued at $3,391,667.16. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Alfonso G. Zulueta sold 19,500 shares of the company’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $112.91, for a total value of $2,201,745.00. Following the completion of the sale, the senior vice president now owns 38,306 shares of the company’s stock, valued at $4,325,130.46. The disclosure for this sale can be found here. Over the last quarter, insiders acquired 8,405 shares of company stock valued at $909,004 and sold 614,373 shares valued at $70,546,895. 0.11% of the stock is currently owned by corporate insiders.

LLY has been the subject of a number of recent analyst reports. UBS Group dropped their price objective on Eli Lilly And Co from $134.00 to $133.00 and set a “buy” rating for the company in a report on Thursday, October 17th. Bank of America initiated coverage on Eli Lilly And Co in a report on Wednesday, October 16th. They set a “buy” rating and a $133.00 price objective for the company. Six equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $130.03.

LLY opened at $113.53 on Friday. The business has a fifty day moving average of $110.61 and a 200 day moving average of $112.67. Eli Lilly And Co has a 52-week low of $101.36 and a 52-week high of $132.13. The company has a quick ratio of 0.88, a current ratio of 1.17 and a debt-to-equity ratio of 4.09. The stock has a market cap of $106.81 billion, a P/E ratio of 20.46, a PEG ratio of 1.82 and a beta of 0.16.

Eli Lilly And Co (NYSE:LLY) last issued its earnings results on Wednesday, October 23rd. The company reported $1.48 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.43 by $0.05. Eli Lilly And Co had a return on equity of 107.99% and a net margin of 35.10%. The business had revenue of $5.48 billion during the quarter, compared to analysts’ expectations of $5.50 billion. During the same period in the prior year, the business earned $1.39 EPS. The business’s revenue for the quarter was up 3.2% compared to the same quarter last year. Equities analysts anticipate that Eli Lilly And Co will post 5.78 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be issued a $0.645 dividend. This represents a $2.58 annualized dividend and a dividend yield of 2.27%. The ex-dividend date of this dividend is Thursday, November 14th. Eli Lilly And Co’s dividend payout ratio is 46.49%.

Eli Lilly And Co Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Story: How does inflation affect different investments?

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply